⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

Official Title: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01)

Study ID: NCT06353022

Study Description

Brief Summary: This is a Phase 2 study, open-label, 2-cohort, multicenter, national, interventional in patients with newly diagnosed multiple myeloma. The study will investigate teclistamab (Tec) in combination with lenalidomide (Len) (Tec-Len; Cohort A) or in combination with talquetamab (Tal) (Tec-Tal; Cohort B), allocated based on minimal residual disease (MRD) status (MRD \[-\] \[standard-risk\] vs MRD \[+\] \[high-risk\] respectively). The patient population will consist of adults men and women at least 18 years to younger than 66 years of age, who meet eligibility criteria.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

CH de la Côte Basque, Bayonne, , France

CHU Caen, Caen, , France

CHRU DIjon, Dijon, , France

Chd Vendee, La Roche-sur-Yon, , France

CHRU LILLE - Hôpital Claude Huriez, Lille, , France

CHU Limoges, Limoges, , France

CH Lyon Sud, Lyon, , France

IPC Marseille Institut Paoli Calmettes, Marseille, , France

CHU Montpellier, Montpellier, , France

CHU de Nantes, Nantes, , France

APHP Hôpital Saint Louis, Paris, , France

APHP Hôpital Saint-Antoine, Paris, , France

APHP Hôpital La Pitié Salpétrière, Paris, , France

CHU BORDEAUX - Hôpital du Haut Lévêque, Pessac, , France

CHU Poitiers, Poitiers, , France

CHRU Rennes - Hôpital de Pontchaillou, Rennes, , France

ICANS Institut de Cancérologie Strasbourg Europe, Strasbourg, , France

CHU Toulouse, Toulouse, , France

CHU Tours Hôpital Bretonneau, Tours, , France

CHRU Nancy - Hôpitaux de Brabois, Vandœuvre-lès-Nancy, , France

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: